Simple blood test after heparin could spot High-Risk pregnancies

NCT ID NCT02855047

Completed Knowledge-focused Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study followed 513 women with antiphospholipid syndrome starting a new pregnancy. Researchers measured two blood markers (PGF and sFlt1) before and after the first low-molecular-weight heparin injections. The goal was to see if changes in these markers could predict serious pregnancy complications like preeclampsia, placental abruption, or poor fetal growth. The study is completed and aims to improve monitoring, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: low-molecular-weight heparin
What this could lead to: If successful, this could help doctors predict which pregnancies are at risk for complications like preeclampsia or fetal growth restriction.
What could go wrong: This is an observational study, not a treatment trial. It only measures markers and does not test a new therapy, so it may not directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANTIPHOSPHOLIPID SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

antiphospholipid syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANTIPHOSPHOLIPID SYNDROME

Contacts and locations

Locations

CHU de Nîmes - Hôpital Universitaire Carémea

Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.